Kenji Arakawa

Find an error

Name:
Organization: Hiroshima University
Department: Department of Molecular Biotechnology, Graduate School of Advanced Sciences of Matter
Title:
Co-reporter:Zhisheng Cao, Ryuhei Yoshida, Haruyasu Kinashi and Kenji Arakawa
The Journal of Antibiotics 2015 68(5) pp:328-333
Publication Date(Web):December 3, 2014
DOI:10.1038/ja.2014.160
In our effort to find the key intermediates of lankacidin biosynthesis in Streptomyces rochei, three UV-active compounds were isolated from mutant FS18, a gene disruptant of lkcA encoding a non-ribosomal peptide synthetase (NRPS)-polyketide synthase (PKS) hybrid enzyme. Their structures were elucidated on the basis of spectroscopic data of NMR and MS. Two compounds of a higher mobile spot on silica gel TLC (Rf=0.45 in CHCl3-MeOH=20:1) were determined to be an epimeric mixture of citreodiol and epi-citreodiol at the C-6 position in the ratio of 2:1. In contrast, the compound of a lower mobile spot (Rf=~0 in CHCl3-MeOH=20:1) was identical to a 28-membered polyene macrolide pentamycin. The yields of citreodiols and pentamycin in FS18 were 5- and 250-fold higher compared with the parent strain. Introduction of a second mutation of srrX, coding a biosynthetic gene of the signaling molecules SRBs, into mutant FS18 did not affect the production of three metabolites. Thus, their production was not regulated by the SRB signaling molecules in contrast to lankacidin or lankamycin.
Co-reporter:Hirofumi Kunitake;Takahiro Hiramatsu;Dr. Haruyasu Kinashi ;Dr. Kenji Arakawa
ChemBioChem 2015 Volume 16( Issue 15) pp:2237-2243
Publication Date(Web):
DOI:10.1002/cbic.201500393

Abstract

Streptomyces rochei 7434AN4 predominantly produces lankacidin and lankamycin under normal culture conditions, thus suggesting that other biosynthetic gene clusters for secondary metabolites are silent. To identify the silent metabolites of 7434AN4, we constructed mutant KA57 with multiple disruptions of the transcriptional repressor srrB and the biosynthesis genes for both antibiotics. KA57 accumulated a compound (KA57A) with a strong UV absorption at 235 nm, not detected in the parent strain or other mutants. Various spectroscopic analyses revealed that KA57A is an azoxyalkene compound with the molecular formula C10H20N2O3 and with the R configuration at C-2. Biosynthesis of KA57A was also studied by feeding with labeled acetates, amino acids, and 1-hexylamine. The hexenyl moiety (C1′–C6′) was derived from fatty acid, whereas the 3-aminobutan-1,2-diol moiety (C1–C4) was derived from C-2 of acetate (C1) and serine (C2–C4). Incorporation of [1,1-2H2]-1-hexylamine indicated that C1′–C2′ dehydrogenation occurs as the final step of biosynthesis.

Co-reporter: Dr. Kenji Arakawa;Naoto Tsuda;Akihiro Taniguchi ; Dr. Haruyasu Kinashi
ChemBioChem 2012 Volume 13( Issue 10) pp:1447-1457
Publication Date(Web):
DOI:10.1002/cbic.201200149

Abstract

New signaling molecules that induce lankacidin and lankamycin production in Streptomyces rochei were extracted from the culture filtrate and purified by Sephadex LH20 and silica gel chromatography with the help of bioassay. Chiral HPLC and ESI-MS analyses indicated the presence of two active components—SRB1 and SRB2—and their molecular formulas were established to be C15H24O5 and C16H26O5, respectively. By extensive NMR analysis, SRB1 and SRB2 were determined to be 2-(1′-hydroxy-6′-oxo-8′-methylnonyl)-3-methyl-4-hydroxybut-2-en-1,4-olide and 2-(1′-hydroxy-6′-oxo-8′-methyldecyl)-3-methyl-4-hydroxybut-2-en-1,4-olide, respectively. These structures were finally confirmed by chemical synthesis and the absolute configuration at C-1′ was determined to be R in each case. The synthetic 1′R isomers induced production of lankacidin and lankamycin at around 40 nM concentrations. SRB1 and SRB2 are therefore distinct from the well-known 2,3-disubstituted γ-butyrolactone molecules such as A-factor, virginia butanolide, and SCB1 and and belong, like avenolide, recently isolated from Streptomyces avermitilis, to the γ-butenolide family.

Co-reporter:Kenji Arakawa, Zhisheng Cao, Natsumi Suzuki, Haruyasu Kinashi
Tetrahedron 2011 67(29) pp: 5199-5205
Publication Date(Web):
DOI:10.1016/j.tet.2011.05.047
epi-citreodiol
methyl (2E,4E,6R,7R)-6,7-dihydroxy-2,6-dimethylocta-2,4-dienoate
Propanamide,N-[(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-hydroxy-,(2S)- (9CI)
Propanamide,N-[(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-13-(acetyloxy)-7-hydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-hydroxy-,(2S)-
(3r,4s,6s,8s,10r,12r,14r,15r,16r,17e,19e,21e,23e,25e,27s,28r)-4,6,8,10,12,14,15,16,27-nonahydroxy-3-[(1r)-1-hydroxyhexyl]-17,28-dimethyl-1-oxacyclooctacosa-17,19,21,23,25-pentaen-2-one
Oxacyclotetradecane-2,10-dione,4-[(4-O-acetyl-2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-xylo-hexopyranosyl)oxy]-12-(acetyloxy)-6-[(4,6-dideoxy-3-O-methyl-b-D-xylo-hexopyranosyl)oxy]-9-hydroxy-14-[(1S,2S)-2-hydroxy-1-methylpropyl]-3,5,7,9,11,13-hexamethyl-,(3R,4S,5R,6S,7S,9S,11R,12S,13S,14R)-
Propanamide,N-[(1S,2R,3E,5E,7S,9E,11E,13S,15R,19R)-7,13-dihydroxy-1,4,10,19-tetramethyl-17,18-dioxo-16-oxabicyclo[13.2.2]nonadeca-3,5,9,11-tetraen-2-yl]-2-oxo-